1 Neuroendocrine Carcinoma Drugs Market Overview 1.1 Product Overview and Scope of Neuroendocrine Carcinoma Drugs 1.2 Neuroendocrine Carcinoma Drugs Segment by Type 1.2.1 Global Neuroendocrine Carcinoma Drugs Sales Growth Rate Comparison by Type (2021-2027) 1.2.2 Somatostatin Analogs 1.2.3 Targeted Therapy 1.2.4 Chemotherapy 1.3 Neuroendocrine Carcinoma Drugs Segment by Application 1.3.1 Global Neuroendocrine Carcinoma Drugs Sales Comparison by Application: (2021-2027) 1.3.2 Hospital 1.3.3 Clinics 1.3.4 Oncology Centres 1.3.5 Ambulatory Surgery Centres 1.4 Global Neuroendocrine Carcinoma Drugs Market Size Estimates and Forecasts 1.4.1 Global Neuroendocrine Carcinoma Drugs Revenue 2016-2027 1.4.2 Global Neuroendocrine Carcinoma Drugs Sales 2016-2027 1.4.3 Neuroendocrine Carcinoma Drugs Market Size by Region: 2016 Versus 2021 Versus 2027 2 Neuroendocrine Carcinoma Drugs Market Competition by Manufacturers 2.1 Global Neuroendocrine Carcinoma Drugs Sales Market Share by Manufacturers (2016-2021) 2.2 Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Manufacturers (2016-2021) 2.3 Global Neuroendocrine Carcinoma Drugs Average Price by Manufacturers (2016-2021) 2.4 Manufacturers Neuroendocrine Carcinoma Drugs Manufacturing Sites, Area Served, Product Type 2.5 Neuroendocrine Carcinoma Drugs Market Competitive Situation and Trends 2.5.1 Neuroendocrine Carcinoma Drugs Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest Neuroendocrine Carcinoma Drugs Players Market Share by Revenue 2.5.3 Global Neuroendocrine Carcinoma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Neuroendocrine Carcinoma Drugs Retrospective Market Scenario by Region 3.1 Global Neuroendocrine Carcinoma Drugs Retrospective Market Scenario in Sales by Region: 2016-2021 3.2 Global Neuroendocrine Carcinoma Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021 3.3 North America Neuroendocrine Carcinoma Drugs Market Facts & Figures by Country 3.3.1 North America Neuroendocrine Carcinoma Drugs Sales by Country 3.3.2 North America Neuroendocrine Carcinoma Drugs Revenue by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Neuroendocrine Carcinoma Drugs Market Facts & Figures by Country 3.4.1 Europe Neuroendocrine Carcinoma Drugs Sales by Country 3.4.2 Europe Neuroendocrine Carcinoma Drugs Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Neuroendocrine Carcinoma Drugs Market Facts & Figures by Region 3.5.1 Asia Pacific Neuroendocrine Carcinoma Drugs Sales by Region 3.5.2 Asia Pacific Neuroendocrine Carcinoma Drugs Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Neuroendocrine Carcinoma Drugs Market Facts & Figures by Country 3.6.1 Latin America Neuroendocrine Carcinoma Drugs Sales by Country 3.6.2 Latin America Neuroendocrine Carcinoma Drugs Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa Neuroendocrine Carcinoma Drugs Market Facts & Figures by Country 3.7.1 Middle East and Africa Neuroendocrine Carcinoma Drugs Sales by Country 3.7.2 Middle East and Africa Neuroendocrine Carcinoma Drugs Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 UAE 4 Global Neuroendocrine Carcinoma Drugs Historic Market Analysis by Type 4.1 Global Neuroendocrine Carcinoma Drugs Sales Market Share by Type (2016-2021) 4.2 Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Type (2016-2021) 4.3 Global Neuroendocrine Carcinoma Drugs Price by Type (2016-2021) 5 Global Neuroendocrine Carcinoma Drugs Historic Market Analysis by Application 5.1 Global Neuroendocrine Carcinoma Drugs Sales Market Share by Application (2016-2021) 5.2 Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Application (2016-2021) 5.3 Global Neuroendocrine Carcinoma Drugs Price by Application (2016-2021) 6 Key Companies Profiled 6.1 Xiaflex 6.1.1 Xiaflex Corporation Information 6.1.2 Xiaflex Description and Business Overview 6.1.3 Xiaflex Neuroendocrine Carcinoma Drugs Sales, Revenue and Gross Margin (2016-2021) 6.1.4 Xiaflex Neuroendocrine Carcinoma Drugs Product Portfolio 6.1.5 Xiaflex Recent Developments/Updates 6.2 Novartis AG 6.2.1 Novartis AG Corporation Information 6.2.2 Novartis AG Description and Business Overview 6.2.3 Novartis AG Neuroendocrine Carcinoma Drugs Sales, Revenue and Gross Margin (2016-2021) 6.2.4 Novartis AG Neuroendocrine Carcinoma Drugs Product Portfolio 6.2.5 Novartis AG Recent Developments/Updates 6.3 Roche 6.3.1 Roche Corporation Information 6.3.2 Roche Description and Business Overview 6.3.3 Roche Neuroendocrine Carcinoma Drugs Sales, Revenue and Gross Margin (2016-2021) 6.3.4 Roche Neuroendocrine Carcinoma Drugs Product Portfolio 6.3.5 Roche Recent Developments/Updates 6.4 Molecular Insight pharmaceuticals 6.4.1 Molecular Insight pharmaceuticals Corporation Information 6.4.2 Molecular Insight pharmaceuticals Description and Business Overview 6.4.3 Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Product Portfolio 6.4.5 Molecular Insight pharmaceuticals Recent Developments/Updates 6.5 Callisto Pharmaceuticals 6.5.1 Callisto Pharmaceuticals Corporation Information 6.5.2 Callisto Pharmaceuticals Description and Business Overview 6.5.3 Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Sales, Revenue and Gross Margin (2016-2021) 6.5.4 Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Product Portfolio 6.5.5 Callisto Pharmaceuticals Recent Developments/Updates 7 Neuroendocrine Carcinoma Drugs Manufacturing Cost Analysis 7.1 Neuroendocrine Carcinoma Drugs Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Neuroendocrine Carcinoma Drugs 7.4 Neuroendocrine Carcinoma Drugs Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Neuroendocrine Carcinoma Drugs Distributors List 8.3 Neuroendocrine Carcinoma Drugs Customers 9 Neuroendocrine Carcinoma Drugs Market Dynamics 9.1 Neuroendocrine Carcinoma Drugs Industry Trends 9.2 Neuroendocrine Carcinoma Drugs Growth Drivers 9.3 Neuroendocrine Carcinoma Drugs Market Challenges 9.4 Neuroendocrine Carcinoma Drugs Market Restraints 10 Global Market Forecast 10.1 Neuroendocrine Carcinoma Drugs Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Neuroendocrine Carcinoma Drugs by Type (2022-2027) 10.1.2 Global Forecasted Revenue of Neuroendocrine Carcinoma Drugs by Type (2022-2027) 10.2 Neuroendocrine Carcinoma Drugs Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Neuroendocrine Carcinoma Drugs by Application (2022-2027) 10.2.2 Global Forecasted Revenue of Neuroendocrine Carcinoma Drugs by Application (2022-2027) 10.3 Neuroendocrine Carcinoma Drugs Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Neuroendocrine Carcinoma Drugs by Region (2022-2027) 10.3.2 Global Forecasted Revenue of Neuroendocrine Carcinoma Drugs by Region (2022-2027) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Neuroendocrine Carcinoma Drugs Sales (K MT) Growth Rate Comparison by Type (2021-2027) Table 2. Global Neuroendocrine Carcinoma Drugs Sales (K MT) Comparison by Application (2021-2027) Table 3. Global Neuroendocrine Carcinoma Drugs Market Size by Region (US$ Million) (2016 VS 2021 VS 2027) Table 4. Key Manufacturers Neuroendocrine Carcinoma Drugs Covered in This Study Table 5. Global Neuroendocrine Carcinoma Drugs Sales (K MT) of Key Manufacturers (2016-2021) Table 6. Global Neuroendocrine Carcinoma Drugs Sales Market Share by Manufacturers (2016-2021) Table 7. Global Neuroendocrine Carcinoma Drugs Revenue (US$ Million) by Manufacturers (2016-2021) Table 8. Global Neuroendocrine Carcinoma Drugs Revenue Share by Manufacturers (2016-2021) Table 9. Global Market Neuroendocrine Carcinoma Drugs Average Price (USD/MT) of Key Manufacturers (2016-2021) Table 10. Manufacturers Neuroendocrine Carcinoma Drugs Manufacturing Sites and Area Served Table 11. Manufacturers Neuroendocrine Carcinoma Drugs Product Type Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Neuroendocrine Carcinoma Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Carcinoma Drugs as of 2020) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Neuroendocrine Carcinoma Drugs Sales by Region (2016-2021) & (K MT) Table 16. Global Neuroendocrine Carcinoma Drugs Sales Market Share by Region (2016-2021) Table 17. Global Neuroendocrine Carcinoma Drugs Revenue by Region (2016-2021) & (US$ Million) Table 18. North America Neuroendocrine Carcinoma Drugs Sales by Country (2016-2021) & (K MT) Table 19. North America Neuroendocrine Carcinoma Drugs Sales Market Share by Country (2016-2021) Table 20. North America Neuroendocrine Carcinoma Drugs Revenue by Country (2016-2021) & (US$ Million) Table 21. North America Neuroendocrine Carcinoma Drugs Revenue Market Share by Country (2016-2021) Table 22. Europe Neuroendocrine Carcinoma Drugs Sales by Country (2016-2021) & (K MT) Table 23. Europe Neuroendocrine Carcinoma Drugs Sales Market Share by Country (2016-2021) Table 24. Europe Neuroendocrine Carcinoma Drugs Revenue by Country (2016-2021) & (US$ Million) Table 25. Europe Neuroendocrine Carcinoma Drugs Revenue Market Share by Country (2016-2021) Table 26. Asia Pacific Neuroendocrine Carcinoma Drugs Sales by Region (2016-2021) & (K MT) Table 27. Asia Pacific Neuroendocrine Carcinoma Drugs Sales Market Share by Region (2016-2021) Table 28. Asia Pacific Neuroendocrine Carcinoma Drugs Revenue by Region (2016-2021) & (US$ Million) Table 29. Asia Pacific Neuroendocrine Carcinoma Drugs Revenue Market Share by Region (2016-2021) Table 30. Latin America Neuroendocrine Carcinoma Drugs Sales by Country (2016-2021) & (K MT) Table 31. Latin America Neuroendocrine Carcinoma Drugs Sales Market Share by Country (2016-2021) Table 32. Latin America Neuroendocrine Carcinoma Drugs Revenue by Country (2016-2021) & (US$ Million) Table 33. Latin America Neuroendocrine Carcinoma Drugs Revenue Market Share by Country (2016-2021) Table 34. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales by Country (2016-2021) & (K MT) Table 35. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Market Share by Country (2016-2021) Table 36. Middle East and Africa Neuroendocrine Carcinoma Drugs Revenue by Country (2016-2021) & (US$ Million) Table 37. Middle East and Africa Neuroendocrine Carcinoma Drugs Revenue Market Share by Country (2016-2021) Table 38. Global Neuroendocrine Carcinoma Drugs Sales (K MT) by Type (2016-2021) Table 39. Global Neuroendocrine Carcinoma Drugs Sales Market Share by Type (2016-2021) Table 40. Global Neuroendocrine Carcinoma Drugs Revenue (Million US$) by Type (2016-2021) Table 41. Global Neuroendocrine Carcinoma Drugs Revenue Share by Type (2016-2021) Table 42. Global Neuroendocrine Carcinoma Drugs Price (USD/MT) by Type (2016-2021) Table 43. Global Neuroendocrine Carcinoma Drugs Sales (K MT) by Application (2016-2021) Table 44. Global Neuroendocrine Carcinoma Drugs Sales Market Share by Application (2016-2021) Table 45. Global Neuroendocrine Carcinoma Drugs Revenue (Million US$) by Application (2016-2021) Table 46. Global Neuroendocrine Carcinoma Drugs Revenue Share by Application (2016-2021) Table 47. Global Neuroendocrine Carcinoma Drugs Price (USD/MT) by Application (2016-2021) Table 48. Xiaflex Corporation Information Table 49. Xiaflex Description and Business Overview Table 50. Xiaflex Neuroendocrine Carcinoma Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 51. Xiaflex Neuroendocrine Carcinoma Drugs Product Table 52. Xiaflex Recent Developments/Updates Table 53. Novartis AG Corporation Information Table 54. Novartis AG Description and Business Overview Table 55. Novartis AG Neuroendocrine Carcinoma Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 56. Novartis AG Neuroendocrine Carcinoma Drugs Product Table 57. Novartis AG Recent Developments/Updates Table 58. Roche Corporation Information Table 59. Roche Description and Business Overview Table 60. Roche Neuroendocrine Carcinoma Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 61. Roche Neuroendocrine Carcinoma Drugs Product Table 62. Roche Recent Developments/Updates Table 63. Molecular Insight pharmaceuticals Corporation Information Table 64. Molecular Insight pharmaceuticals Description and Business Overview Table 65. Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 66. Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Product Table 67. Molecular Insight pharmaceuticals Recent Developments/Updates Table 68. Callisto Pharmaceuticals Corporation Information Table 69. Callisto Pharmaceuticals Description and Business Overview Table 70. Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 71. Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Product Table 72. Callisto Pharmaceuticals Recent Developments/Updates Table 73. Production Base and Market Concentration Rate of Raw Material Table 74. Key Suppliers of Raw Materials Table 75. Neuroendocrine Carcinoma Drugs Distributors List Table 76. Neuroendocrine Carcinoma Drugs Customers List Table 77. Neuroendocrine Carcinoma Drugs Market Trends Table 78. Neuroendocrine Carcinoma Drugs Growth Drivers Table 79. Neuroendocrine Carcinoma Drugs Market Challenges Table 80. Neuroendocrine Carcinoma Drugs Market Restraints Table 81. Global Neuroendocrine Carcinoma Drugs Sales Forecast by Type (2022-2027) & (K MT) Table 82. Global Neuroendocrine Carcinoma Drugs Sales Market Share Forecast by Type (2022-2027) Table 83. Global Neuroendocrine Carcinoma Drugs Revenue Forecast by Type (2022-2027) & (US$ Million) Table 84. Global Neuroendocrine Carcinoma Drugs Revenue Market Share Forecast by Type (2022-2027) Table 85. Global Neuroendocrine Carcinoma Drugs Sales Forecast by Application (2022-2027) & (K MT) Table 86. Global Neuroendocrine Carcinoma Drugs Sales Market Share Forecast by Application (2022-2027) Table 87. Global Neuroendocrine Carcinoma Drugs Revenue Forecast by Application (2022-2027) & (US$ Million) Table 88. Global Neuroendocrine Carcinoma Drugs Revenue Market Share Forecast by Application (2022-2027) Table 89. Global Neuroendocrine Carcinoma Drugs Sales Forecast by Region (2022-2027) & (K MT) Table 90. Global Neuroendocrine Carcinoma Drugs Sales Market Share Forecast by Region (2022-2027) Table 91. Global Neuroendocrine Carcinoma Drugs Revenue Forecast by Region (2022-2027) & (US$ Million) Table 92. Global Neuroendocrine Carcinoma Drugs Revenue Market Share Forecast by Region (2022-2027) Table 93. Research Programs/Design for This Report Table 94. Key Data Information from Secondary Sources Table 95. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Neuroendocrine Carcinoma Drugs Figure 2. Global Neuroendocrine Carcinoma Drugs Market Share by Type in 2020 & 2027 Figure 3. Somatostatin Analogs Product Picture Figure 4. Targeted Therapy Product Picture Figure 5. Chemotherapy Product Picture Figure 6. Global Neuroendocrine Carcinoma Drugs Market Share by Application in 2020 & 2027 Figure 7. Hospital Figure 8. Clinics Figure 9. Oncology Centres Figure 10. Ambulatory Surgery Centres Figure 11. Global Neuroendocrine Carcinoma Drugs Revenue, (US$ Million), 2016 VS 2021 VS 2027 Figure 12. Global Neuroendocrine Carcinoma Drugs Market Size 2016-2027 (US$ Million) Figure 13. Global Neuroendocrine Carcinoma Drugs Sales 2016-2027 (K MT) Figure 14. Global Neuroendocrine Carcinoma Drugs Market Size Market Share by Region: 2016 VS 20210 VS 2027 Figure 15. Neuroendocrine Carcinoma Drugs Sales Share by Manufacturers in 2020 Figure 16. Global Neuroendocrine Carcinoma Drugs Revenue Share by Manufacturers in 2020 Figure 17. The Global 5 and 10 Largest Neuroendocrine Carcinoma Drugs Players: Market Share by Revenue in 2020 Figure 18. Neuroendocrine Carcinoma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021 Figure 19. Global Neuroendocrine Carcinoma Drugs Sales Market Share by Region (2016-2021) Figure 20. Global Neuroendocrine Carcinoma Drugs Sales Market Share by Region in 2020 Figure 21. Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Region (2016-2021) Figure 22. Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Region in 2020 Figure 23. U.S. Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 24. Canada Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 25. Germany Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 26. France Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 27. U.K. Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 28. Italy Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 29. Russia Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 30. China Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 31. Japan Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 32. South Korea Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 33. India Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 34. Australia Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 35. Taiwan Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 36. Indonesia Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 37. Thailand Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 38. Malaysia Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 39. Philippines Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 40. Vietnam Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 41. Mexico Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 42. Brazil Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 43. Argentina Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 44. Turkey Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 45. Saudi Arabia Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 46. UAE Neuroendocrine Carcinoma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 47. Sales Market Share of Neuroendocrine Carcinoma Drugs by Type (2016-2021) Figure 48. Sales Market Share of Neuroendocrine Carcinoma Drugs by Application (2016-2021) Figure 49. Sales Market Share of Neuroendocrine Carcinoma Drugs by Application in 2020 Figure 50. Revenue Share of Neuroendocrine Carcinoma Drugs by Application (2016-2021) Figure 51. Revenue Share of Neuroendocrine Carcinoma Drugs by Application in 2020 Figure 52. Manufacturing Cost Structure of Neuroendocrine Carcinoma Drugs Figure 53. Manufacturing Process Analysis of Neuroendocrine Carcinoma Drugs Figure 54. Neuroendocrine Carcinoma Drugs Industrial Chain Analysis Figure 55. Channels of Distribution Figure 56. Distributors Profiles Figure 57. Bottom-up and Top-down Approaches for This Report Figure 58. Data Triangulation Figure 59. Key Executives Interviewed

Xiaflex Novartis AG Roche Molecular Insight pharmaceuticals Callisto Pharmaceuticals